Evidence map›Paper›PMID 39757653›Full record

ArticleCurrent medical imaging2025

A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients

Tianyu Zhao, Chunjing Zhang, Hang Dai, Jingyu Li, Liguo Hao, Yanan Liu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianyu ZhaoMedical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.
Chunjing ZhangMedical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.
Hang DaiForeign Language Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.
Jingyu LiMedical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.
Liguo HaoMedical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.
Yanan LiuMedical Technology Department, Qiqihar Medical University, Qiqihar 161006, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe study aims to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

methodWe retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG, n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG, n=40, treated solely with targeted therapy).

resultsThe OG group reported 4 cases of Complete Response (CR), 24 cases of Partial Response (PR), 10 cases of Stable Disease (SD), and 2 cases of Progressive Disease (PD). The Overall Response Rate (ORR) was 70.00% (28/40), and the Disease Control Rate (DCR) was 95.00% (38/40). In contrast, the CG group exhibited 3 cases of CR, 20 cases of PR, 12 cases of SD, and 5 cases of PD. The ORR was 57.50% (23/40), and the DCR was 87.50% (35/40). The ORR and DCR in the OG group were significantly higher than those in the CG group. After 6 weeks of treatment, the levels of SCC, CEA, and CA125 in the OG group were significantly lower than those in the CG group; The CD4+ levels in the OG group were significantly higher and the CD8+ levels significantly lower than those in the CG group. A 24-month follow-up showed that the survival rate of the OG group was 47.50% (19/40), which was significantly higher than that of the CG group at 27.50% (11/40).

conclusionCT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

Indexed as

Lung NeoplasmsMolecular Targeted TherapyRadiofrequency AblationTomography, X-Ray ComputedAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeClinical efficacyImmune responseLung cancerRadiofrequency ablationSafetySurvival timeTargeted therapy

Identifiers

PMID39757653
PMCPMC12933225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.